CRISPR Therapeutics (CRSP) News Today $43.80 -0.40 (-0.91%) As of 11:48 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period MaxCyte: Building the Future of Cell and Gene Therapy Innovation (CRSP)MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy.January 23 at 7:00 AM | marketbeat.comMy Top 5 Stocks to Buy in Early 2025January 23 at 4:15 AM | fool.comCantor Fitzgerald Comments on CRSP FY2025 EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of CRISPR Therapeutics in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst E. Schmidt expects that the companyJanuary 23 at 2:25 AM | marketbeat.comRFK disclosures show holdings in Crispr, Dragonfly Therapeutics, STAT reportsJanuary 22 at 11:14 PM | markets.businessinsider.comCRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Rating of "Hold" by BrokeragesShares of CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) have earned a consensus rating of "Hold" from the nineteen research firms that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, eight have assignedJanuary 22 at 2:57 AM | marketbeat.comCRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest Up 5.4% in DecemberCRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) saw a large growth in short interest in December. As of December 31st, there was short interest totalling 19,100,000 shares, a growth of 5.4% from the December 15th total of 18,120,000 shares. Based on an average daily volume of 1,670,000 shares, the short-interest ratio is presently 11.4 days.January 19, 2025 | marketbeat.comCathie Wood’s ARK Investment bought 147K shares of Crispr Therapeutics todayJanuary 18, 2025 | markets.businessinsider.comCRISPR Therapeutics AG (CRSP): The Biotech Stock with Biggest Upside PotentialJanuary 17, 2025 | msn.comCathie Wood’s ARK Investment bought 133K shares of Crispr Therapeutics todayJanuary 17, 2025 | markets.businessinsider.comMirador Capital Partners LP Invests $297,000 in CRISPR Therapeutics AG (NASDAQ:CRSP)Mirador Capital Partners LP bought a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 7,536 shares of the company's stock, valued at approximately $29January 17, 2025 | marketbeat.comCRISPR Therapeutics' SWOT analysis: gene editing pioneer's stock faces pivotal yearJanuary 16, 2025 | msn.com2 bold stock market ideas to consider for a Stocks and Shares ISAJanuary 16, 2025 | msn.comPromising Developments and Strategic Partnerships Drive Crispr Therapeutics’ Growth PotentialJanuary 16, 2025 | markets.businessinsider.com2 Magnificent Stocks to Buy That Are Near Their 52-Week LowsJanuary 16, 2025 | fool.comMy 10 Top Stocks to Buy to Start the New Year Off RightJanuary 16, 2025 | fool.comCRISPR Therapeutics: Unfairly Punished By The Issues Of Its PeersJanuary 15, 2025 | seekingalpha.comCRISPR Therapeutics (NASDAQ:CRSP) Reaches New 1-Year Low - Time to Sell?CRISPR Therapeutics (NASDAQ:CRSP) Reaches New 52-Week Low - Here's WhyJanuary 15, 2025 | marketbeat.comCrispr Therapeutics AG: Strategic Pipeline Progress and Financial Strength Drive Buy RatingJanuary 15, 2025 | markets.businessinsider.comCRISPR Therapeutics AG (CRSP) 43rd Annual JPMorgan Healthcare Conference - (Transcript)January 14, 2025 | seekingalpha.comCRISPR Therapeutics' (CRSP) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC reiterated a "buy" rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a report on Tuesday.January 14, 2025 | marketbeat.comMeet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street AnalystsJanuary 14, 2025 | fool.comBuy Rating for Crispr Therapeutics AG: Strong Pipeline, Strategic Partnerships, and Financial Stability Drive ConfidenceJanuary 13, 2025 | markets.businessinsider.comCRISPR Therapeutics (NASDAQ:CRSP) Sets New 12-Month Low - Should You Sell?CRISPR Therapeutics (NASDAQ:CRSP) Sets New 52-Week Low - Time to Sell?January 13, 2025 | marketbeat.comCRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2025 MilestonesJanuary 13, 2025 | markets.businessinsider.com1 growth stock that could soar 105%, according to Wall Street expertsJanuary 11, 2025 | msn.comCatherine Wood's Recent Transaction with CRISPR Therapeutics AGJanuary 10, 2025 | gurufocus.comBrookline Capital Management Estimates CRSP FY2024 EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Investment analysts at Brookline Capital Management boosted their FY2024 EPS estimates for shares of CRISPR Therapeutics in a research note issued to investors on Monday, January 6th. Brookline Capital Management analyst L. Cann now expects thaJanuary 9, 2025 | marketbeat.com3 Mid-Cap Stocks That Could Take Off in 2025January 9, 2025 | fool.comCRISPR Therapeutics AG (CRSP) to Present at J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | gurufocus.comCRISPR Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceJanuary 8, 2025 | globenewswire.comBrokers Offer Predictions for CRSP FY2029 EarningsCRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) - Equities researchers at Brookline Capital Management issued their FY2029 earnings per share (EPS) estimates for CRISPR Therapeutics in a research report issued to clients and investors on Monday, January 6th. Brookline Capital Management analysJanuary 8, 2025 | marketbeat.comCrispr Therapeutics proposes to elect Briggs Morrison to boardJanuary 7, 2025 | markets.businessinsider.comCrispr Therapeutics price target lowered to $85 from $98 at BofAJanuary 7, 2025 | markets.businessinsider.comBank of America Lowers CRISPR Therapeutics (NASDAQ:CRSP) Price Target to $85.00Bank of America cut their target price on shares of CRISPR Therapeutics from $98.00 to $85.00 and set a "buy" rating on the stock in a research note on Tuesday.January 7, 2025 | marketbeat.comCheck Out What Whales Are Doing With CRSPJanuary 7, 2025 | benzinga.com2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space.January 7, 2025 | marketbeat.comCRISPR Therapeutics AG (CRSP) Announces Proposed Election of Briggs Morrison, M.D. ...January 7, 2025 | gurufocus.com11,715 Shares in CRISPR Therapeutics AG (NASDAQ:CRSP) Purchased by Capital Market Strategies LLCCapital Market Strategies LLC acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 11,715 shares of the company's stock, valued at aJanuary 6, 2025 | marketbeat.comCrispr Therapeutics call volume above normal and directionally bullishJanuary 1, 2025 | markets.businessinsider.comCRISPR Therapeutics (NASDAQ:CRSP) Upgraded by StockNews.com to Sell RatingStockNews.com upgraded shares of CRISPR Therapeutics to a "sell" rating in a report on Monday.December 30, 2024 | marketbeat.comWhy Is CRISPR Therapeutics AG (CRSP) Among the Top CRISPR Stocks to Invest In?December 30, 2024 | msn.comCRISPR Therapeutics (NASDAQ:CRSP) Reaches New 12-Month Low - Here's WhyCRISPR Therapeutics (NASDAQ:CRSP) Reaches New 12-Month Low - Time to Sell?December 30, 2024 | marketbeat.comCRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | msn.comCrispr Therapeutics: From Casgevy Success To A Catalyst-Rich 2025December 29, 2024 | seekingalpha.comCRISPR Therapeutics AG (CRSP): Is This Gene Therapy Stock a Good Buy Right Now?December 29, 2024 | insidermonkey.comCathie Wood’s ARK Investment bought 58K shares of Crispr Therapeutics todayDecember 27, 2024 | markets.businessinsider.comInstitutional investors may adopt severe steps after CRISPR Therapeutics AG's (NASDAQ:CRSP) latest 8.3% drop adds to a year lossesDecember 25, 2024 | finance.yahoo.comGeode Capital Management LLC Has $47.38 Million Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP)Geode Capital Management LLC lifted its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 3.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,008,214 shares of the company's stock after purchasing an additional 35,196 shares durDecember 24, 2024 | marketbeat.comThis Beaten-Down Biotech Stock Just Got Some Good News: Time to Buy?December 22, 2024 | fool.com1 big new Green Flag for CRISPR Therapeutics' StockDecember 20, 2024 | fool.com Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address CRSP Media Mentions By Week CRSP Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRSP News Sentiment▼0.750.63▲Average Medical News Sentiment CRSP News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRSP Articles This Week▼1610▲CRSP Articles Average Week Get CRISPR Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRSP and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Moderna News Bio-Techne News Vaxcyte News Qiagen News Exelixis News Repligen News Halozyme Therapeutics News Revolution Medicines News Krystal Biotech News Scholar Rock News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRSP) was last updated on 1/23/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredMust-See: 5-Second Trump PredictionPresident Trump's prediction is about to become a reality... Opening a rare window of opportunity for you t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CRISPR Therapeutics AG Please log in to your account or sign up in order to add this asset to your watchlist. Share CRISPR Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRSP Stock Alerts